$AIM
AIM ImmunoTech Inc. Stock $aim

$aim Overview Financials Valuation SEC Filings Company Website

2022 Q3 Form 10-Q Financial Statement

#000149315222022600 Filed on August 15, 2022

Income Statement

Concept	2022 Q3	2022 Q2	2022 Q1
Revenue	$21.00K	$30.00K	$33.00K
YoY Change	-36.36%	30.43%	17.86%
Cost Of Revenue	$0.00	$69.00K	$77.00K
YoY Change	-100.0%	-86.65%	-67.51%
Gross Profit	$21.00K	-$39.00K	-$44.00K
YoY Change	-116.94%	-91.61%	-78.95%
Gross Profit Margin	100.0%	-130.0%	-133.33%
Selling, General & Admin	$5.170M	$2.181M	$2.072M
YoY Change	187.38%	-48.75%	-1.89%
% of Gross Profit	24619.05%
Research & Development	$1.372M	$2.475M	$1.036M
YoY Change	-31.61%	87.93%	-27.25%
% of Gross Profit	6533.33%
Depreciation & Amortization	$28.00K	$29.00K	$29.00K
YoY Change	-84.09%	-83.71%	-87.22%
% of Gross Profit	133.33%
Operating Expenses	$1.372M	$2.475M	$3.108M
YoY Change	-63.94%	87.93%	-12.1%
Operating Profit	-$6.521M	-$4.695M	-$3.152M
YoY Change	65.97%	26.28%	-15.83%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	$172.0K	$3.000K	$31.00K
YoY Change	237.25%	-110.34%	-183.78%
Pretax Income	-$6.385M	-$4.851M	-$3.820M
YoY Change	66.88%	-48.69%	6.73%
Income Tax
% Of Pretax Income
Net Earnings	-$6.385M	-$4.851M	-$3.820M
YoY Change	66.88%	-17.44%	6.73%
Net Earnings / Revenue	-30404.76%	-16170.0%	-11575.76%
Basic Earnings Per Share	-$0.13	-$0.10	-$0.08
Diluted Earnings Per Share	-$132.8K	-$101.0K	-$79.59K
COMMON SHARES
Basic Shares Outstanding	48.05M shares
Diluted Shares Outstanding	48.08M shares	48.03M shares

Balance Sheet

Concept	2022 Q3	2022 Q2	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$36.75M	$41.77M	$44.54M
YoY Change	-2.91%	1.53%	-10.8%
Cash & Equivalents	$29.76M	$34.45M	$28.99M
Short-Term Investments	$6.986M	$7.320M	$15.55M
Other Short-Term Assets	$4.405M	$4.273M	$4.196M
YoY Change	2636.02%	2656.77%	2555.7%
Inventory
Prepaid Expenses
Receivables	$0.00	$0.00	$1.641M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$41.15M	$46.05M	$50.38M
YoY Change	8.18%	11.42%	-1.64%
LONG-TERM ASSETS
Property, Plant & Equipment	$118.0K	$127.0K	$281.0K
YoY Change	-98.08%	-97.98%	-95.66%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$2.138M	$1.811M	$1.506M
YoY Change	71.18%	53.87%	62.11%
Total Long-Term Assets	$5.135M	$4.839M	$3.775M
YoY Change	-79.5%	-80.95%	-83.49%
TOTAL ASSETS
Total Short-Term Assets	$41.15M	$46.05M	$50.38M
Total Long-Term Assets	$5.135M	$4.839M	$3.775M
Total Assets	$46.29M	$50.88M	$54.16M
YoY Change	-26.62%	-23.74%	-26.91%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$957.0K	$712.0K	$378.0K
YoY Change	159.35%	57.87%	100.0%
Accrued Expenses	$1.767M	$502.0K	$388.0K
YoY Change	343.97%	18.12%	-29.07%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$2.895M	$1.368M	$766.0K
YoY Change	277.44%	56.16%	-21.03%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Other Long-Term Liabilities	$695.0K	$736.0K	$88.00K
YoY Change	161.28%	134.39%	-73.81%
Total Long-Term Liabilities	$695.0K	$736.0K	$88.00K
YoY Change			-95.91%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.895M	$1.368M	$766.0K
Total Long-Term Liabilities	$695.0K	$736.0K	$88.00K
Total Liabilities	$3.590M	$2.104M	$854.0K
YoY Change	247.53%	76.81%	-72.65%
SHAREHOLDERS EQUITY
Retained Earnings	-$376.2M	-$369.8M
YoY Change
Common Stock	$48.00K	$417.8M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$42.70M	$48.78M	$53.30M
YoY Change
Total Liabilities & Shareholders Equity	$46.29M	$50.88M	$54.16M
YoY Change	-26.62%	-23.74%	-26.91%

Cashflow Statement

Concept	2022 Q3	2022 Q2	2022 Q1
OPERATING ACTIVITIES
Net Income	-$6.385M	-$4.851M	-$3.820M
YoY Change	66.88%	-17.44%	6.73%
Depreciation, Depletion And Amortization	$28.00K	$29.00K	$29.00K
YoY Change	-84.09%	-83.71%	-87.22%
Cash From Operating Activities	-$4.968M	-$2.313M	-$2.758M
YoY Change	43.71%	34.63%	-9.43%
INVESTING ACTIVITIES
Capital Expenditures	-$20.00K	-$43.00K	-$33.00K
YoY Change	-77.01%	65.38%	-90.96%
Acquisitions
YoY Change
Other Investing Activities	$270.0K	$7.764M	-$313.0K
YoY Change	-196.77%	-789.52%	-135.25%
Cash From Investing Activities	$250.0K	$7.721M	-$346.0K
YoY Change	-168.31%	-770.23%	-166.16%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	25.00K	55.00K
YoY Change	-16.67%	-101.16%
NET CHANGE
Cash From Operating Activities	-4.968M	-2.313M	-2.758M
Cash From Investing Activities	250.0K	7.721M	-346.0K
Cash From Financing Activities	25.00K	55.00K
Net Change In Cash	-4.693M	5.463M	$0.00
YoY Change	23.73%	-171.59%	-100.0%
FREE CASH FLOW
Cash From Operating Activities	-$4.968M	-$2.313M	-$2.758M
Capital Expenditures	-$20.00K	-$43.00K	-$33.00K
Free Cash Flow	-$4.948M	-$2.270M	-$2.725M
YoY Change	46.82%	34.16%	1.68%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0000946644
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Transition Report DocumentTransitionReport	false
CY2021Q2	us-gaap	Gain Loss On Investments GainLossOnInvestments		usd
	us-gaap	Gain Loss On Investments GainLossOnInvestments		usd
CY2022Q2	us-gaap	Interest Expense InterestExpense		usd
	us-gaap	Interest Expense InterestExpense		usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2022Q2	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1		usd
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1		usd
CY2022Q2	AIM	Reclassification Adjustment For Realized Investment Lost ReclassificationAdjustmentForRealizedInvestmentLost		usd
	AIM	Reclassification Adjustment For Realized Investment Lost ReclassificationAdjustmentForRealizedInvestmentLost		usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax		usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax		usd
CY2022Q2	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities		usd
CY2021Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities		usd
	AIM	Extinguishment Of Financing Obligation And Note Payables ExtinguishmentOfFinancingObligationAndNotePayables		usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment		usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts		usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable		usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets		usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment		usd
	AIM	Payment Of Financing Obligation PaymentOfFinancingObligation		usd
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt		usd
	AIM	Operating Leaseright Of Use Assets OperatingLeaserightOfUseAssets		usd
	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss		usd
CY2021	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss		usd
CY2022Q2	AIM	Accrued Clinical Trial Expenses Current AccruedClinicalTrialExpensesCurrent		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Period End Date DocumentPeriodEndDate	2022-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Entity File Number EntityFileNumber	001-27072
	dei	Entity Registrant Name EntityRegistrantName	AIM IMMUNOTECH INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	52-0845822
	dei	Entity Address Address Line1 EntityAddressAddressLine1	2117 SW Highway 484
	dei	Entity Address City Or Town EntityAddressCityOrTown	Ocala
	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	34473
	dei	City Area Code CityAreaCode	(352)
	dei	Local Phone Number LocalPhoneNumber	448-7797
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
	dei	Trading Symbol TradingSymbol	AIM
	dei	Security Exchange Name SecurityExchangeName	NYSE
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	48049300	shares
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	34452000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	32093000	usd
CY2022Q2	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	7320000	usd
CY2021Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	16175000	usd
CY2021Q4	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	1641000	usd
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	373000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	304000	usd
CY2022Q2	us-gaap	Assets Held For Sale Not Part Of Disposal Group Current AssetsHeldForSaleNotPartOfDisposalGroupCurrent	3900000	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	46045000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	50213000	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	127000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4047000	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	889000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	149000	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2012000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1974000	usd
CY2022Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1811000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1316000	usd
CY2022Q2	us-gaap	Assets Assets	50884000	usd
CY2021Q4	us-gaap	Assets Assets	57699000	usd
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	712000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	198000	usd
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	502000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	438000	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	154000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	37000	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	1368000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	673000	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	735000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	112000	usd
CY2022Q2	AIM	Redeemable Warrants RedeemableWarrants	1000	usd
CY2021Q4	AIM	Redeemable Warrants RedeemableWarrants	35000	usd
CY2022Q2	us-gaap	Preferred Stock Value PreferredStockValue	713000	usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	715000	usd
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	48048822	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	48048822	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	47994672	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	47994672	shares
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	48000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	48000	usd
CY2022Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	417791000	usd
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	417217000	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-369772000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-361101000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	48780000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	56879000	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	50884000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	57699000	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	30000	usd
CY2021Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	23000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	64000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	52000	usd
CY2022Q2	us-gaap	Manufacturing Costs ManufacturingCosts	69000	usd
CY2021Q2	us-gaap	Manufacturing Costs ManufacturingCosts	279000	usd
	us-gaap	Manufacturing Costs ManufacturingCosts	147000	usd
	us-gaap	Manufacturing Costs ManufacturingCosts	517000	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2475000	usd
CY2021Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1317000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3511000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2742000	usd
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2181000	usd
CY2021Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2145000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4253000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4256000	usd
CY2022Q2	us-gaap	Costs And Expenses CostsAndExpenses	4725000	usd
CY2021Q2	us-gaap	Costs And Expenses CostsAndExpenses	3741000	usd
	us-gaap	Costs And Expenses CostsAndExpenses	7911000	usd
	us-gaap	Costs And Expenses CostsAndExpenses	7515000	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-4695000	usd
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-3718000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-7847000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-7463000	usd
CY2022Q2	us-gaap	Gain Loss On Investments GainLossOnInvestments	-470000	usd
	us-gaap	Gain Loss On Investments GainLossOnInvestments	-1404000	usd
CY2022Q2	us-gaap	Interest And Other Income InterestAndOtherIncome	79000	usd
CY2021Q2	us-gaap	Interest And Other Income InterestAndOtherIncome	51000	usd
	us-gaap	Interest And Other Income InterestAndOtherIncome	124000	usd
	us-gaap	Interest And Other Income InterestAndOtherIncome	120000	usd
CY2021Q2	us-gaap	Interest Expense InterestExpense	19000	usd
	us-gaap	Interest Expense InterestExpense	67000	usd
CY2021Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-2701000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-2701000	usd
CY2021Q2	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	216000	usd
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	216000	usd
CY2022Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-3000	usd
CY2021Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-7000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-34000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	29000	usd
CY2022Q2	AIM	Gain From Sale Of Income Tax Operating Loss GainFromSaleOfIncomeTaxOperatingLoss	-232000	usd
CY2021Q2	AIM	Gain From Sale Of Income Tax Operating Loss GainFromSaleOfIncomeTaxOperatingLoss	-288000	usd
	AIM	Gain From Sale Of Income Tax Operating Loss GainFromSaleOfIncomeTaxOperatingLoss	-422000	usd
	AIM	Gain From Sale Of Income Tax Operating Loss GainFromSaleOfIncomeTaxOperatingLoss	-469000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-4851000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-5876000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-8671000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-9455000	usd
CY2021Q2	AIM	Reclassification Adjustment For Realized Investment Lost ReclassificationAdjustmentForRealizedInvestmentLost	25000	usd
	AIM	Reclassification Adjustment For Realized Investment Lost ReclassificationAdjustmentForRealizedInvestmentLost	25000	usd
CY2021Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-62000	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-225000	usd
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4851000	usd
CY2021Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5913000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-8671000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-9655000	usd
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.10
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.12
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.18
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.20
CY2022Q2	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	48034100	shares
CY2021Q2	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	47832997	shares
	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	48014713	shares
	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	46805492	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	56879000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	242000	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3820000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	53301000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	55000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	275000	usd
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4851000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	48780000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	61294000	usd
CY2021Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	12887000	usd
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	526000	usd
CY2021Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3742000	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	70965000	usd
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	480000	usd
CY2021Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5913000	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	65532000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-8671000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-9455000	usd
	us-gaap	Depreciation Depreciation	20000	usd
	us-gaap	Depreciation Depreciation	325000	usd
	AIM	Redeemable Warrants Valuation Adjustment RedeemableWarrantsValuationAdjustment	-34000	usd
	AIM	Redeemable Warrants Valuation Adjustment RedeemableWarrantsValuationAdjustment	29000	usd
	AIM	Extinguishment Of Financing Obligation And Note Payables ExtinguishmentOfFinancingObligationAndNotePayables	2701000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	38000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	80000	usd
	AIM	Increase Decreasein Rightof Use Assets IncreaseDecreaseinRightofUseAssets	-740000	usd
	AIM	Increase Decreasein Rightof Use Assets IncreaseDecreaseinRightofUseAssets	22000	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	216000	usd
	AIM	Gain From Sale Of Income Tax Operating Losses GainFromSaleOfIncomeTaxOperatingLosses	-422000	usd
	AIM	Gain From Sale Of Income Tax Operating Losses GainFromSaleOfIncomeTaxOperatingLosses	-469000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	517000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1006000	usd
	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	-1404000	usd
	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	-25000	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	47000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-6000	usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-1641000	usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-1090000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	69000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-69000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	740000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-22000	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	73000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	514000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	68000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	64000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-69000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5071000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4763000	usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	8713000	usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	1613000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	1262000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	2096000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	26000	usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	245000	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	76000	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	365000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	7375000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-629000	usd
	AIM	Payment Of Financing Obligation PaymentOfFinancingObligation	4732000	usd
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	122000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	55000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	12887000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	55000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	8033000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	2359000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	2641000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	32093000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	38501000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	34452000	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	41142000	usd
	AIM	Operating Leaseright Of Use Assets OperatingLeaserightOfUseAssets	761000	usd
	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-225000	usd
	AIM	Conversion Of Series B Preferred ConversionOfSeriesBPreferred	2000	usd
	AIM	Conversion Of Series B Preferred ConversionOfSeriesBPreferred	7000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	300000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
	us-gaap	Share Based Compensation ShareBasedCompensation	517000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1006000	usd
CY2022Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	454000	usd
CY2021Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	434000	usd
CY2022Q2	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	7320000	usd
CY2021Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	16175000	usd
CY2022Q2	us-gaap	Marketable Securities MarketableSecurities	7320000	usd
CY2022Q2	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	7320000	usd
	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	-1404000	usd
	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss	-583000	usd
	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-821000	usd
CY2021Q4	us-gaap	Marketable Securities MarketableSecurities	16175000	usd
CY2021Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	16175000	usd
CY2021	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	-88000	usd
CY2021	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-88000	usd
	us-gaap	Depreciation Depreciation	325000	usd
CY2021	us-gaap	Asset Impairment Charges AssetImpairmentCharges	1800000	usd
CY2022Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y8M1D
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y8M19D
	AIM	Percentage Of Incremental Borrowing Rate PercentageOfIncrementalBorrowingRate	0.10	pure
CY2021	AIM	Percentage Of Incremental Borrowing Rate PercentageOfIncrementalBorrowingRate	0.10	pure
CY2022Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	28000	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1000	usd
CY2022Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	344000	usd
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	169000	usd
CY2021Q4	AIM	Accrued Clinical Trial Expenses Current AccruedClinicalTrialExpensesCurrent	61000	usd
CY2022Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	130000	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	207000	usd
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	502000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	438000	usd
CY2022Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2353000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	6253000	usd
CY2022Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2226000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2206000	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	127000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4047000	usd
	us-gaap	Depreciation Depreciation	20000	usd
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1498000	usd
CY2021	us-gaap	Finitelived Intangible Assets Acquired1 FinitelivedIntangibleAssetsAcquired1	592000	usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	116000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1974000	usd
	us-gaap	Finitelived Intangible Assets Acquired1 FinitelivedIntangibleAssetsAcquired1	76000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	38000	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2012000	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	40000	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	156000	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	180000	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	203000	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	240000	usd
CY2022Q2	AIM	Finite Lived Intangible Assets Amortization Expense After Year Four FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour	1193000	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2012000	usd
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2022Q2	AIM	Common Stock Shares With Limitations And Restrictions On Usage CommonStockSharesWithLimitationsAndRestrictionsOnUsage	8000000	shares
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2022Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	15000	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	48048822	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	47994672	shares
CY2018Q1	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y
CY2018Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	73314	shares
CY2018Q1	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y
CY2018Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	17.05
CY2018Q1	AIM	Warrant Closing Price Percentages WarrantClosingPricePercentages	1.25	pure
CY2021Q2	us-gaap	Payments To Acquire Other Property Plant And Equipment PaymentsToAcquireOtherPropertyPlantAndEquipment	4732637	usd
	AIM	Floor Rate Used As Proxy For Future Volatility Percentage FloorRateUsedAsProxyForFutureVolatilityPercentage	1	pure
CY2022Q2	us-gaap	Derivative Assets DerivativeAssets	7320000	usd
CY2022Q2	us-gaap	Derivative Liabilities DerivativeLiabilities	1000	usd
CY2021Q4	us-gaap	Derivative Assets DerivativeAssets	16175000	usd
CY2021Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	35000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Fair Value Disclosure PropertyPlantAndEquipmentFairValueDisclosure	3900000	usd
CY2021	us-gaap	Gain Loss On Fair Value Hedge Ineffectiveness Net GainLossOnFairValueHedgeIneffectivenessNet	-1800000	usd
CY2021	us-gaap	Property Plant And Equipment Collections Not Capitalized Deaccessed Fair Value PropertyPlantAndEquipmentCollectionsNotCapitalizedDeaccessedFairValue	3900000	usd
CY2021	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	1800000	usd
CY2018Q1	us-gaap	Proceeds From Sale Of Buildings ProceedsFromSaleOfBuildings	4080000	usd
CY2018Q1	us-gaap	Lessee Operating Lease Description LesseeOperatingLeaseDescription	lease the property back for ten years at $408,000 per year for two years through March 31, 2020. The lease payments would increase 2.5% per year for the next three years through March 31, 2023, and the lease payments would increase 3% for the remaining five years through March 31, 2028
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	54000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	153000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	174000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	158000	usd
CY2022Q2	AIM	Lessee Operating Lease Liability Payments Due After Year Three LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree	373000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	23000	usd
CY2022Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	889000	usd
CY2022Q2	AIM	Operating Leases Right Of Use Asset OperatingLeasesRightOfUseAsset	889000	usd
CY2021Q4	AIM	Operating Leases Right Of Use Asset OperatingLeasesRightOfUseAsset	149000	usd
CY2022Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	889000	usd
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	149000	usd
	us-gaap	Payments For Rent PaymentsForRent	34000	usd
	us-gaap	Payments For Rent PaymentsForRent	22000	usd
	us-gaap	Short Term Lease Payments ShortTermLeasePayments	10000	usd
	us-gaap	Short Term Lease Payments ShortTermLeasePayments	10000	usd

Files In Submission

Name	View Source	Status
0001493152-22-022600-index-headers.html	Edgar Link	pending
0001493152-22-022600-index.html	Edgar Link	pending
0001493152-22-022600.txt	Edgar Link	pending
0001493152-22-022600-xbrl.zip	Edgar Link	pending
aim-20220630.xsd	Edgar Link	pending
aim-20220630_cal.xml	Edgar Link	unprocessable
aim-20220630_def.xml	Edgar Link	unprocessable
ex10-86.htm	Edgar Link	pending
ex10-87.htm	Edgar Link	pending
ex10-88.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
aim-20220630_pre.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
FilingSummary.xml	Edgar Link	unprocessable
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
aim-20220630_lab.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AIM
AIM ImmunoTech Inc. Stock $aim

2022 Q3 Form 10-Q Financial Statement

#000149315222022600 Filed on August 15, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AIM AIM ImmunoTech Inc. Stock $aim

2022 Q3 Form 10-Q Financial Statement

#000149315222022600 Filed on August 15, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AIM
AIM ImmunoTech Inc. Stock $aim